Cargando…
We can study ultrarare tumors effectively in this day and age, it just takes a cooperative approach: The role of dasatinib in assorted indolent sarcomas
Dasatinib may be an active agent in assorted indolent sarcomas. The impact of endpoint selection, well‐defined cohorts, and responses (Choi criteria vs Response Evaluation Criteria in Solid Tumors) are discussed. See also pages 90‐7.
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215314/ https://www.ncbi.nlm.nih.gov/pubmed/27696384 http://dx.doi.org/10.1002/cncr.30377 |